Luminal CCK-releasing factors in the isolated vascularly perfused rat duodenojejunum.
The factors operating at the apical side of the endocrine cell releasing cholecystokinin (CCK) were investigated using the isolated vascularly perfused rat duodenojejunum. In the protease-free intestinal segment, a 30-min infusion of glucose (280 mM), oleic acid (100 mM), or triglycerides containing short- or long-chain fatty acids did not alter significantly the basal level of portal CCK-like immunoreactivity (CCK-LI), while octanoic acid (100 mM) produced a transient rise of plasma CCK-LI to approximately 250% of basal. Infusion of proteins (5% solutions of ovalbumin or casein) or of a mixture of all amino acids brought about a modest CCK secretion. In contrast, isocaloric amounts of an ovalbumin hydrolysate produced a sharp rise of portal CCK-LI to 530% of basal followed by a well-sustained plateau secretion (420% of basal) until the end of the infusion. An acid casein hydrolysate induced a slightly less pronounced CCK-LI release and was followed in decreasing order by meat, casein, and soybean peptones. Simultaneous infusion of trypsin with ovalbumin or casein hydrolysate reduced by approximately 60% the CCK release induced by peptone alone. This effect was reversed by coinfusion of soybean trypsin inhibitor (SBTI) with the trypsin-peptone mixture. Arterial infusion of tetrodotoxin (10(-6) M) or atropine (10(-5) M) had no significant effect on the trypsin-induced inhibition of peptone-mediated CCK-LI release. Administration of SBTI or camostate alone or in combination with trypsin did not alter basal CCK. Monitor peptide produced a dose-dependent transient rise of portal CCK-LI over the range from 2 to 12 micrograms.(ABSTRACT TRUNCATED AT 250 WORDS)
Cuber
J C
JC
Institut National de la Santé et de la Recherche Médicale U45, Hôpital Edouard Herriot, Lyon.
Bernard
G
G
Fushiki
T
T
Bernard
C
C
Yamanishi
R
R
Sugimoto
E
E
Chayvialle
J A
JA
D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D002766:Cholecystokinin / Q000378:metabolism*; D004386:Duodenum / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology*; D006133:Growth Substances; D066298:In Vitro Techniques; D036341:Intercellular Signaling Peptides and Proteins; D007583:Jejunum / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009130:Muscle, Smooth / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D010477:Perfusion; D011506:Proteins / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology*
D000596:Amino Acids; D005768:Gastrointestinal Hormones; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; C504705:Spink1 protein, rat; D014361:Trypsin Inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic; D002766:Cholecystokinin; D005947:Glucose